RxDoctor Payments Data

Rosann Giesting

Adult Health · Fairfield, OHNPI 1508882598

Payments from drug & device makers

$3,168in general payments, 2019–2025

Across 172 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$732
  • Abbott$333
  • Novartis$313
  • Amgen$268
  • Pfizer$251
  • AstraZeneca$220
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,154100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,168 in reported general payments places this provider in the 85th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$107,886
Medicare patients
405
Services billed
1,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan415$400,021
JardianceEmpagliflozin182$214,368
FarxigaDapagliflozin Propanediol36$43,701
EliquisApixaban11$17,663
Midodrine Hcl79$6,162
Spironolactone525$2,835
Metoprolol Succinate263$2,731
Valsartan165$2,729
Digoxin134$2,507
Carvedilol268$2,461
Torsemide122$2,388
Furosemide458$1,827
Diltiazem 12hr ErDiltiazem Hcl12$1,523
Hydralazine Hcl82$804
Isosorbide Mononitrate ErIsosorbide Mononitrate62$570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$313$400,021415 claims
Boehringer IngelheimJardiance$732$214,368182 claims
AstraZenecaFarxiga$220$43,70136 claims
PfizerEliquis$251$17,66311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,184 adult health providers in Ohio.

Other adult health in Fairfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →